While we can't dismiss another generic copaxone competitor, there are a couple of items that make it a bit less likely than with generic lovenox. First, the competing Mylan version was acquired from an Indian generic company, and was made for a market with lower approval standards. One could also argue that copaxone might be a little tougher to copy, which favors Momenta's abilities. And finally, the FDA will likely tweak the approval process so as not to give away so many trade secrets this time.
The profit split is unaffected by the # of entrants, so you were not understanding correctly on that point at all.
Regards, RockRat
Market Data 
Markets 
AI
